Clinical Impact of GEP in cSCC

In this episode, “Clinical Impact of GEP in cSCC,” the panelists explore the growing evidence supporting the use of gene expression profiling (GEP) in identifying patients with cutaneous squamous cell carcinoma (cSCC) at increased risk for recurrence and metastasis. The expert faculty discuss the expanding body of validation data supporting DecisionDx-SCC and how molecular profiling may provide prognostic information beyond traditional clinicopathologic staging systems.

The panel reviews how GEP results are incorporated into multidisciplinary tumor board discussions and how these findings may influence treatment escalation, de-escalation, and individualized care planning. The expert faculty highlight how molecular profiling can identify patients with seemingly low-stage disease who may benefit from adjuvant radiation therapy or closer surveillance, while also helping clinicians avoid overtreatment in select patients with traditionally high-risk tumors.

Additionally, the discussion examines how GEP results are used alongside clinical judgment, patient comorbidities, and shared decision-making to guide recommendations regarding imaging, radiation therapy, and follow-up intensity. The panel also compares the evolving use of molecular profiling in cSCC with precision medicine approaches already established in other oncology settings, including breast cancer. Throughout the discussion, the expert faculty emphasize the importance of integrating validated molecular data into personalized treatment strategies to improve patient outcomes and refine risk stratification in cSCC management.

The next episode in this series, “Limitations of GEP in cSCC,” features the panelists discussing practical considerations surrounding implementation of gene expression profiling in clinical practice, including access, utilization, and incorporation into multidisciplinary care pathways for patients with cSCC.